Copyright
©The Author(s) 2015.
World J Clin Infect Dis. Feb 25, 2015; 5(1): 1-10
Published online Feb 25, 2015. doi: 10.5495/wjcid.v5.i1.1
Published online Feb 25, 2015. doi: 10.5495/wjcid.v5.i1.1
Ref. | N | Time since transplant | Vaccine | Technique | Response to immunization | Long term immune response |
Silberman et al[59] | 27 KT vs 24 healthy adults | 7-108 mo | 14-valent | Indirect hemagglutination | 4-fold increase in titers, equivalent to controls | Not studied |
Marrie et al[60] | 63 KT vs 8 healthy adults | 3-99 mo | 14-valent | RIA | 2.8-fold increase in titers in KT vs 3.4-fold in controls | GMT in KT: 872 ng N/mL post-vaccine 659 ng N/mL at 12 mo |
Cosio et al[61] | 25 KT (14 asplenia) vs 14 healthy adults | 3-118 mo | 14-valent | RIA | 2-fold increase in titers in 93% of 14 healthy adults vs 78% of 14 splenectomized KT and 55% of 11 non-splenectomized KT patients | Not studied |
Linneman et al[62,63] | 104 KT (79 asplenia) vs 33 patients in hemodialysis | No data | 14-valent | RIA | 1.4-fold increase in antibody titers: 91%GMT post-vaccine with lower response in splenectomized KT vs non-splenectomized KT patients (394 vs 626 ng N/mL, P < 0.05) GMT post-vaccine with lower response in KT patients before 6 mo after transplant vs hemodialysis patients (303 vs 592 ng N/mL, P < 0.05) | GMT at 24 mo in 33 KT: 932 ng N/mL post-vaccine 385 ng N/mL at 24 mo 536 ng N/mL at revaccination |
Arnold et al[64] | 75 KT (32 asplenia) vs 60 healthy controls | > 12 mo | 14-valent | Serum opsonizing antibody | 2-fold increase in titers to serotypes 12F and 14 No differences in splenectomized vs non-splenectomized KT recipients | Not studied |
Rytel et al[65] | 61 KT (57 asplenia) vs 23 patients in dialysis vs 9 healthy controls | > 6 mo | 14-valent | RIA | Equivalent protective GMT titers vs controls | Equivalent at 1, 2, and 3.5 yr vs controls |
Kazancioglu et al[69] | 21 KT vs 25 healthy controls | > 2 mo | PPV23 | ELISA | Protective response to vaccination (40% increases in the antibody concentration) in 95.2% of KT at 1.5 and 3 mo after vaccination | Not studied |
Kumar et al[78,79] | 30 KT (PPV23) vs 30 KT (PCV7) | 3 mo-3 yr | PPV23 vs PCV7 | ELISA, OPA | Response to at least 1 serotype: no significant differences in antibody titers between PPV23 and PVC7, both using ELISA (53.3% vs 73.3%) and OPA (83.3% vs 80%) | Vaccine responses decline significantly after 3 yr and conjugate vaccine does not improve the durability of response |
- Citation: Roca-Oporto C, Pachón-Ibañez ME, Pachón J, Cordero E. Pneumococcal disease in adult solid organ transplantation recipients. World J Clin Infect Dis 2015; 5(1): 1-10
- URL: https://www.wjgnet.com/2220-3176/full/v5/i1/1.htm
- DOI: https://dx.doi.org/10.5495/wjcid.v5.i1.1